Analysis on the price of the Indian version of the targeted drug Sotorasibu (AMG510)

Sotorasiib (AMG510), a targeted drug targeting KRAS G12C mutated advanced non-small cell lung cancer (NSCLC), has attracted widespread attention in the global pharmaceutical market. However, there is some misunderstanding and confusion regarding its price scenario in India. To be clear, there is currently no officially certified Indian version of the original or generic version of Sotorasibu. Although there is news that sotorasibu may be available in places such as India, there is considerable uncertainty about the source and quality of these medicines. Therefore, when considering purchasing, patients must carefully choose channels to ensure the safety and effectiveness of the drugs.

The original drug of sotoracib has been launched in many countries, including the United States and the European Union. In addition, some overseas countries have produced generic drugs of sotorasibu. These drugs are basically the same in ingredients as the original drugs and are suitable for the treatment of patients with advanced non-small cell lung cancer with specific genetic changes. However, there may be certain differences between generic drugs and original drugs in terms of production specifications and prices. Currently known generic drug manufacturers include Laos Lucius Pharmaceutical Factory and Daxiong Pharmaceutical Factory.

As for the price of sotorasibu, since drug prices may fluctuate over time, the current price of the original drug is roughly between RMB 40,000 and RMB 80,000. The price of generic drugs may be relatively low, around RMB 1-2,000 (the price may fluctuate due to exchange rates).

In short, for patients who need to purchase sotoraxib, it is crucial to choose formal channels and ensure drug quality and safety. At the same time, attention should also be paid to the dynamic changes in drug prices in order to make more informed drug purchasing decisions.